An Exploratory Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer

Trial Profile

An Exploratory Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs Cabazitaxel (Primary) ; Abiraterone acetate; Prednisone
  • Indications Bone metastases; Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Jul 2017 Planned number of patients changed from 80 to 55.
    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Results (n=42) of exploratory analysis evaluating baseline N terminal AR expression in CTCs in men with chemotherapy-naive CPRC and correlated to changes in PSA, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top